NCT03100149

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2017-06-27Est. Completion: 2019-11-27

Enrollment target: 316 participants

Locations

Uab Medicine, Birmingham, Alabama, United States
Barrow Neurology Clinics, Phoenix, Arizona, United States
Neurology Center of North Orange County, Fullerton, California, United States
USC Keck Medical Center of USC, Los Angeles, California, United States
University of California at San Francisco, San Francisco, California, United States
CenExel Rocky Mountain Clinical Research, LLC, Englewood, Colorado, United States
Associated Neurologists of Southern CT PC, Fairfield, Connecticut, United States
Molecular Neurolmaging, New Haven, Connecticut, United States
Aventura Neurologic Associates, Aventura, Florida, United States
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
USF Parkinsons Disease and Movement Disorders Center, Tampa, Florida, United States
Northwestern University, Evanston, Illinois, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Quest Research Institute, Farmington Hills, Michigan, United States

Parkinson Disease (PD)

The goal of this pilot clinical trial is to learn whether a week-long study combining controlled breathing procedures, i…

Multiple LocationsEst. completion Nov 2026

Parkinson DeseaseMild Cognitive Impairment (MCI)

The OPERA Clinical Study is an interventional, single-arm, open-label pilot clinical study that aims to evaluate the usa…

Sant'Angelo dei Lombardi, ItalyCompleted Oct 31, 2025

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.